ArticleJournal of cheminformatics2026
PL-PatchSurfer3: improved structure-based virtual screening for structure variation using 3D Zernike descriptors.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SHREC 2025: Protein surface shape retrieval including electrostatic potential.Computers & graphics · 2025Article
- Article
- ZMPY3D: accelerating protein structure volume analysis through vectorized 3D Zernike moments and Python-based GPU integration.Bioinformatics advances · 2024Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Structure-based virtual screening (SBVS) is a widely used approach in in silico drug discovery, requiring a receptor structure or binding site to predict a ligand's binding pose and affinity. Consequently, the performance of SBVS depends on the protein's conformation. The most common SBVS method is protein-ligand docking, which relies on physics-based, empirical, or knowledge-based scoring functions to estimate binding affinity. However, these methods are highly sensitive to structural variations and conformational changes of the receptor structure. The performance of SBVS often drops substantially when the apo form of the receptor used for screening is different from its holo form. To address this issue, we previously introduced an SBVS method called PL-PatchSurfer. This method uses a surface representation to describe a binding site of receptors and drug molecules, which is more robust to structural changes, offering more stable screening performance. The surface of the molecules is segmented into patches, and their shapes and physicochemical properties, such as the electrostatic potential, are represented by the 3D Zernike descriptor, a compact and rotationally invariant mathematical representation. Here, we introduce PL-PatchSurfer3, an improved version of PL-PatchSurfer, which incorporates two key enhancements: a refined definition of hydrogen bond complementarity and the integration of visibility, which captures curvature information of a patch. Our evaluation demonstrates that the new program outperforms its predecessor and other SBVS methods while maintaining its robustness against receptor structure variations.Scientific contributionThis study presents PL-PatchSurfer3, an improved surface patch-based virtual screening method that incorporates molecular surface shape, physicochemical properties, hydrogen-bonding compatibility, and visibility, capturing local curvature using rotationally invariant 3D Zernike descriptors. PL-PatchSurfer3 demonstrates robust performance across holo, apo, modeled, and AlphaFold-predicted receptor structures and is superior to or competitive with conventional approaches and recent deep learning-based methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.